Every 8-K that Evommune, Inc. (EVMN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow EVMN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EVMN filings page.
Evommune, Inc. reported Phase 2a proof-of-concept results for EVO301 in adults with moderate-to-severe atopic dermatitis. The 70-patient trial used intravenous doses of 5 mg/kg at baseline and Week 4, with 48 patients receiving EVO301 and 22 receiving placebo. At Week 12, eight weeks after the last dose, the least-squares mean EASI reduction from baseline was 55% with EVO301 versus 22% with placebo (p<0.01); reported reductions at Weeks 4 and 8 were 41% versus 18% and 50% versus 16%.
At Week 12, EASI-50 responses were 63% versus 23%, and EASI-75 responses were 29% versus 9%. Treatment-related adverse events occurred in 10.4% of EVO301-treated patients and 13.6% of placebo patients. Evommune reported no treatment-related serious or severe adverse events, no discontinuations due to adverse events, no clinically significant laboratory abnormalities, and no conjunctivitis. The company plans to initiate a subcutaneous, dose-ranging Phase 2b trial in mid-2027.
Evommune, Inc. announced that data from its Phase 2a trial of EVO301 in moderate-to-severe atopic dermatitis will be presented in a late-breaking oral session at the 2026 European Academy of Dermatology & Venereology Congress in Vienna. The congress runs September 30 to October 3, 2026, with the presentation scheduled for October 1, 2026.
EVO301 is a long-acting injectable SAFA-IL-18BP fusion protein designed to neutralize aberrantly upregulated IL-18 activity. Evommune said its Phase 2b dose-ranging study in moderate-to-severe atopic dermatitis is anticipated to begin in mid-2027.
Evommune, Inc. (EVMN) furnished an updated corporate presentation outlining its strategy to treat chronic inflammatory and immunological diseases through three main programs: EVO301 (an IL‑18 binding protein biologic for atopic dermatitis and other IL‑18–driven diseases), EVO756 (an oral MRGPRX2 antagonist for migraine prevention) and EVO646 (an oral TLR7/8 antagonist for autoimmune diseases).
The presentation reports Phase 2a proof‑of‑concept data for EVO301 in moderate‑to‑severe atopic dermatitis in 70 adults, showing a 34% placebo‑adjusted EASI improvement at week 8 (33% at week 12), with 23% of patients achieving IGA 0/1 at week 12 versus 0% on placebo and no treatment‑related serious or severe adverse events; a Phase 2b subcutaneous dose‑ranging trial is planned to start in mid‑2027. For EVO756, Evommune describes completed Phase 1 and proof‑of‑concept work and an ongoing Phase 2b migraine prevention trial in approximately 330 patients, with top‑line data expected in 2027, while EVO646 is being advanced toward a Phase 1 start in the first half of 2027.
Evommune highlights an estimated $287 million in cash and investments with an expected runway into 2029, large target markets in atopic dermatitis, migraine and autoimmune diseases, and a leadership team that has held key roles in nearly 30 prior NDA and BLA approvals.
Evommune, Inc. (EVMN) reported top-line data from a randomized, double-blind, placebo-controlled, dose-ranging Phase 2b trial of oral MRGPRX2 antagonist EVO756 in adults with moderate-to-severe atopic dermatitis. The 12‑week study in 121 patients did not meet its primary or secondary endpoints at any dose, and Evommune plans to cease development of EVO756 for atopic dermatitis while continuing to evaluate it in migraine prophylaxis.
The company highlighted EVO301, an IL‑18BP fusion protein, as its lead atopic dermatitis program after positive Phase 2a proof‑of‑concept data and plans a Phase 2b trial starting in mid‑2027. Based on revised clinical plans, Evommune expects its current cash, cash equivalents and investments to fund operations into 2029.
Evommune, Inc., a clinical-stage biotechnology company, reported second quarter 2026 results and highlighted progress across its inflammatory disease pipeline. Lead oral candidate EVO756 is in a fully enrolled Phase 2b trial in moderate-to-severe atopic dermatitis, with top-line data expected in September 2026, and a global Phase 2b migraine prophylaxis trial has recently begun, targeting top-line data in 2027. After a Phase 2b chronic spontaneous urticaria study failed to meet its primary endpoint, development of EVO756 in that indication was discontinued to prioritize atopic dermatitis and migraine. Injectable fusion protein EVO301 showed positive Phase 2a data in atopic dermatitis, with full results to be presented at an upcoming medical conference and a Phase 2b trial planned to start in mid-2027, while additional indications such as ulcerative colitis and certain cardiovascular-related inflammatory conditions are being evaluated.
For the quarter ended June 30, 2026, revenue was zero, research and development expense was $26.4 million, and general and administrative expense was $8.5 million, leading to a net loss of $32.2 million. For the first six months of 2026, net loss was $53.9 million. Cash, cash equivalents and investments totaled $288.0 million as of June 30, 2026, compared with $216.7 million at December 31, 2025, and the company states this provides cash runway through 2028.
Evommune, Inc. reports that the first patient has been dosed in a global Phase 2b clinical trial of its oral MRGPRX2 antagonist EVO756 for prophylactic treatment of migraine. The study targets adults with refractory migraine experiencing at least six migraine days per month.
The randomized, double-blind, placebo-controlled, dose-ranging trial will enroll approximately 330 patients across two active doses and placebo for 12 weeks of daily treatment, exploring doses up to 100 mg. The primary endpoint is change in monthly migraine days, with top-line data expected in 2027.
Evommune, Inc. reported top-line results from its Phase 2b trial of oral MRGPRX2 antagonist EVO756 in moderate-to-severe chronic spontaneous urticaria. The randomized, double-blind, placebo-controlled study in 160 antihistamine-refractory patients did not meet the primary endpoint of change in Urticaria Activity Score over seven days at 12 weeks at any dose.
Based on these data, Evommune plans to cease development of EVO756 for chronic spontaneous urticaria, but will continue evaluating the drug in other indications. The company remains on track to report Phase 2b data for EVO756 in atopic dermatitis in the third quarter of 2026 and has begun a Phase 2b trial in migraine prophylaxis.
Evommune also highlighted positive Phase 2a proof-of-concept data in atopic dermatitis for its IL-18BP fusion protein EVO301, and stated it has a strong cash position supporting anticipated operations through 2028, which it believes will allow continued advancement of its inflammatory disease pipeline.
Evommune, Inc. held its 2026 Annual Meeting of Stockholders on June 2, 2026, with a quorum present. Stockholders elected two directors to serve until the 2029 annual meeting or until their successors are elected and qualified.
Luis Peña was elected with 21,859,596 votes for and 1,949,148 votes withheld, while Eugene Bauer, M.D. received 23,637,920 votes for and 170,824 votes withheld. There were 885,750 broker non-votes for each nominee.
Stockholders also ratified the selection of BDO USA, P.C. as Evommune’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with 24,664,299 votes for, 430 votes against, and 29,765 abstentions.
Evommune, Inc. reported first-quarter 2026 results and detailed progress across its chronic inflammation pipeline. Cash, cash equivalents and investments were $307.0 million as of March 31, 2026, up from $216.7 million at year-end 2025, supporting an expected cash runway through 2028.
The company reported no revenue in Q1 2026 versus $3.0 million a year earlier, driven by lower collaboration revenue, and a net loss of $21.7 million, compared with $14.6 million in Q1 2025, as R&D and G&A spending increased.
Evommune highlighted late-stage pipeline catalysts: Phase 2b top-line data for EVO756 in chronic spontaneous urticaria is expected in June 2026 and in atopic dermatitis in the third quarter of 2026, with a Phase 2b migraine prophylaxis trial planned for mid-2026. For EVO301, positive Phase 2a proof-of-concept data in atopic dermatitis support a larger Phase 2b trial using a new subcutaneous formulation planned to start in mid-2027.
Evommune, Inc. furnished a webcast presentation describing the migraine treatment landscape and the scientific rationale for targeting the receptor MRGPRX2 with its oral small-molecule candidate EVO756. The materials outline how mast cells and sensory neurons may drive migraine and position MRGPRX2 inhibition as a potential new preventive approach.
The company highlights EVO756’s development roadmap across multiple inflammatory indications and its plan to initiate a Phase 2b, dose-ranging migraine prophylaxis trial in mid-2026. The presentation also notes high unmet need in migraine prevention, ongoing reliance on legacy preventives, and limitations of current CGRP-based therapies.
Evommune, Inc. reported fourth quarter and full year 2025 results and highlighted major clinical and financing milestones. Revenue reached $13.0 million for 2025, up from $7.0 million in 2024, driven by a licensing collaboration for EVO756 in Japan. Research and development expenses were $74.0 million and general and administrative expenses were $20.0 million, leading to a full year net loss of $68.9 million.
As of December 31, 2025, cash, cash equivalents and investments totaled $216.7 million, and together with a subsequent $125 million private placement in February 2026, are expected to fund operations through 2028. The company reported positive Phase 2a proof‑of‑concept data for EVO301 in atopic dermatitis, with meaningful EASI improvements and a favorable safety profile, and is planning a Phase 2b, Phase 3‑enabling trial. Oral MRGPRX2 antagonist EVO756 is in Phase 2b trials in chronic spontaneous urticaria and atopic dermatitis, with top‑line data expected in the second quarter and second half of 2026, and a migraine trial planned for mid‑2026.
Evommune, Inc. entered into a securities purchase agreement for a private placement of 4,494,279 shares of common stock at $27.88 per share, for expected gross proceeds of about $125 million before expenses. The deal is with a select group of new and existing institutional and healthcare-focused investors and is expected to close on or about February 17, 2026, subject to customary conditions.
Evommune plans to use the net proceeds to advance its clinical development programs and for general corporate purposes. The company also granted investors registration rights, committing to file a Form S-1 to register the resale of these shares and to keep that registration effective until the shares are sold or freely tradable.
Evommune, Inc. reported positive top-line results from a randomized, double-blind, placebo-controlled Phase 2a trial of EVO301 in adults with moderate-to-severe atopic dermatitis. The 70-patient study used two intravenous doses of 5 mg/kg on day 1 and day 28 over 12 weeks.
The trial met its primary endpoint based on a Bayesian analysis of EASI score improvement, with 99.8% of the posterior distribution showing at least an 8% benefit over placebo, far above the 75% success criterion. Using a frequentist method, EVO301 showed statistically significant EASI improvements versus placebo at weeks 4, 8 and 12 with p<0.01.
Placebo-adjusted EASI improvements were 34% at week 8 and 33% at week 12, and 23% of EVO301-treated patients achieved vIGA-AD 0/1 at week 12 compared with 0% on placebo. EVO301 was well tolerated, with no related serious or severe adverse events, no treatment-related discontinuations, and no meaningful safety imbalances. Evommune plans a Phase 2b dose-ranging trial in atopic dermatitis using a subcutaneous formulation and is evaluating additional indications, including ulcerative colitis.
Evommune, Inc. filed a current report to share that it has issued a press release with a business update and its financial results for the third quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and is incorporated by reference. The company notes that this information is being furnished rather than filed, which means it is not subject to certain liability provisions under the securities laws and is not automatically included in other SEC filings unless specifically referenced.